Literature DB >> 31567892

Functional Pancreatic Sphincter Dysfunction in Children: Recommendations for Diagnosis and Management.

Tom K Lin1, Douglas S Fishman2, Matthew J Giefer3, Quin Y Liu4, David Troendle5, Steven Werlin6, Mark E Lowe7, Aliye Uc8.   

Abstract

OBJECTIVE: Functional pancreatic sphincter dysfunction (FPSD), previously characterized as pancreatic sphincter of Oddi dysfunction, is a rarely described cause of pancreatitis. Most studies are reported in adults with alcohol or smoking as confounders, which are uncommon risk factors in children. There are no tests to reliably diagnose FPSD in pediatrics and it is unclear to what degree this disorder contributes to childhood pancreatitis.
METHODS: We conducted a literature review of the diagnostic and treatment approaches for FPSD, including unique challenges applicable to pediatrics. We identified best practices in the management of children with suspected FPSD and formed a consensus expert opinion.
RESULTS: In children with acute recurrent pancreatitis (ARP) or chronic pancreatitis (CP), we recommend that other risk factors, specifically obstructive factors, be ruled out before considering FPSD as the underlying etiology. In children with ARP/CP, FPSD may be the etiology behind a persistently dilated pancreatic duct in the absence of an alternative obstructive process. Endoscopic retrograde cholangiopancreatography with sphincterotomy should be considered in a select group of children with ARP/CP when FPSD is highly suspected and other etiologies have been effectively ruled out. The family and patient should be thoroughly counseled regarding the risks and advantages of endoscopic intervention. Endoscopic retrograde cholangiopancreatography for suspected FPSD should be considered with caution in children with ARP/CP when pancreatic ductal dilatation is absent.
CONCLUSIONS: Our consensus expert guidelines provide a uniform approach to the diagnosis and treatment of pediatric FPSD. Further research is necessary to determine the full contribution of FPSD to pediatric pancreatitis.

Entities:  

Mesh:

Year:  2019        PMID: 31567892      PMCID: PMC6878194          DOI: 10.1097/MPG.0000000000002515

Source DB:  PubMed          Journal:  J Pediatr Gastroenterol Nutr        ISSN: 0277-2116            Impact factor:   2.839


  44 in total

1.  Definitions of pediatric pancreatitis and survey of present clinical practices.

Authors:  Veronique D Morinville; Sohail Z Husain; Harrison Bai; Bradley Barth; Rabea Alhosh; Peter R Durie; Steven D Freedman; Ryan Himes; Mark E Lowe; John Pohl; Steven Werlin; Michael Wilschanski; Aliye Uc
Journal:  J Pediatr Gastroenterol Nutr       Date:  2012-09       Impact factor: 2.839

2.  Can patient and pain characteristics predict manometric sphincter of Oddi dysfunction in patients with clinically suspected sphincter of Oddi dysfunction?

Authors:  Joseph Romagnuolo; Peter B Cotton; Valerie Durkalski; Qi Pauls; Olga Brawman-Mintzer; Douglas A Drossman; Patrick Mauldin; Kyle Orrell; April W Williams; Evan L Fogel; Paul R Tarnasky; Giuseppe Aliperti; Martin L Freeman; Richard A Kozarek; Priya A Jamidar; C Mel Wilcox; Jose Serrano; Grace H Elta
Journal:  Gastrointest Endosc       Date:  2014-01-25       Impact factor: 9.427

3.  Prospective Endoscopic Ultrasound-Based Approach to the Evaluation of Idiopathic Pancreatitis: Causes, Response to Therapy, and Long-term Outcome.

Authors:  C Mel Wilcox; Toni Seay; Hwasoon Kim; Shyam Varadarajulu
Journal:  Am J Gastroenterol       Date:  2016-06-21       Impact factor: 10.864

Review 4.  Dysmotility disturbances of the biliary tract: classification, diagnosis, and treatment.

Authors:  W J Hogan; J E Geenen; W J Dodds
Journal:  Semin Liver Dis       Date:  1987-11       Impact factor: 6.115

5.  Effect of endoscopic sphincterotomy for suspected sphincter of Oddi dysfunction on pain-related disability following cholecystectomy: the EPISOD randomized clinical trial.

Authors:  Peter B Cotton; Valerie Durkalski; Joseph Romagnuolo; Qi Pauls; Evan Fogel; Paul Tarnasky; Giuseppe Aliperti; Martin Freeman; Richard Kozarek; Priya Jamidar; Mel Wilcox; Jose Serrano; Olga Brawman-Mintzer; Grace Elta; Patrick Mauldin; Andre Thornhill; Robert Hawes; April Wood-Williams; Kyle Orrell; Douglas Drossman; Patricia Robuck
Journal:  JAMA       Date:  2014-05       Impact factor: 56.272

6.  Sphincter of Oddi dysfunction is associated with chronic pancreatitis.

Authors:  P R Tarnasky; B Hoffman; L Aabakken; W L Knapple; W Coyle; B Pineau; J T Cunningham; P B Cotton; R H Hawes
Journal:  Am J Gastroenterol       Date:  1997-07       Impact factor: 10.864

7.  Sphincter of Oddi dysfunction in children with recurrent pancreatitis and anomalous pancreaticobiliary union: an etiologic concept.

Authors:  M Guelrud; C Morera; M Rodriguez; D Jaen; R Pierre
Journal:  Gastrointest Endosc       Date:  1999-08       Impact factor: 9.427

8.  Division of the sphincter of Oddi for treatment of dysfunction associated with recurrent pancreatitis.

Authors:  J Toouli; V Di Francesco; G Saccone; J Kollias; A Schloithe; N Shanks
Journal:  Br J Surg       Date:  1996-09       Impact factor: 6.939

9.  Secretin MRCP and endoscopic pancreatic manometry in the evaluation of sphincter of Oddi function: a comparative pilot study in patients with idiopathic recurrent pancreatitis.

Authors:  Alberto Mariani; Simona Curioni; Alessandro Zanello; Sandro Passaretti; Enzo Masci; Marzia Rossi; Alessandro Del Maschio; Pier Alberto Testoni
Journal:  Gastrointest Endosc       Date:  2003-12       Impact factor: 9.427

10.  Similar efficacies of biliary, with or without pancreatic, sphincterotomy in treatment of idiopathic recurrent acute pancreatitis.

Authors:  Gregory A Coté; Thomas F Imperiale; Suzette E Schmidt; Evan Fogel; Glen Lehman; Lee McHenry; James Watkins; Stuart Sherman
Journal:  Gastroenterology       Date:  2012-09-11       Impact factor: 22.682

View more
  1 in total

Review 1.  Demographics and risk factors for pediatric recurrent acute pancreatitis.

Authors:  Cheryl E Gariepy; Chee Y Ooi; Asim Maqbool; Kate M Ellery
Journal:  Curr Opin Gastroenterol       Date:  2021-09-01       Impact factor: 2.741

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.